Peer-reviewedCC BYFrontiers in oncology
ATF4 and SLC7A11 as biomarkers predicting progression and prognosis in lung adenocarcinoma
- 1Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University , ,
- 2Cancer Institute, Fourth Hospital of Hebei Medical University , ,
Related
- An explainable machine learning model combining intratumoral and peritumoral computed tomography radiomics with maximum standard uptake value for predicting International Association for the Study of Lung Cancer grading and prognosis in stage I pure-solid lung adenocarcinoma.
- MRI-based intratumoral and peritumoral heterogeneity for predicting intracranial progression in EGFR-mutant lung adenocarcinoma patients with treatment-naive brain metastases receiving first-line third-generation EGFR-TKIs.
- Metabolic signature of phosphoethanolamine and arginine pathways predicts prognosis and immunotherapy resistance in lung adenocarcinoma
- Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC
- Editorial: AI-powered insights: predicting treatment response and prognosis in breast cancer
BibTeX
@article{liu2026atf4,
title = {{ATF4 and SLC7A11 as biomarkers predicting progression and prognosis in lung adenocarcinoma}},
author = {Yanjie Liu and Dongli Guo and Daojuan Li and Jing Jin},
journal = {Frontiers in oncology},
year = {2026},
month = oct,
url = {https://europepmc.org/article/PMC/PMC13655137},
note = {CC BY},
}
RIS
TY - JOUR
TI - ATF4 and SLC7A11 as biomarkers predicting progression and prognosis in lung adenocarcinoma
AU - Yanjie Liu
AU - Dongli Guo
AU - Daojuan Li
AU - Jing Jin
PY - 2026
DA - 2026/10/16
JO - Frontiers in oncology
UR - https://europepmc.org/article/PMC/PMC13655137
SN - 2234-943X
ER -